Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Regeneron Pharmaceuticals is conducting a Phase 3 study titled A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5). The study aims to evaluate the safety and efficacy of odronextamab combined with lenalidomide compared to the current standard treatment of rituximab with lenalidomide for patients with relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL).
Intervention/Treatment: The study tests odronextamab, an experimental bispecific antibody, in combination with lenalidomide, against the standard treatment of rituximab with lenalidomide. Odronextamab is administered via intravenous infusion, while lenalidomide is taken orally. Rituximab can be administered either intravenously or subcutaneously.
Study Design: This interventional study is randomized with a parallel assignment model and no masking, focusing on treatment as the primary purpose. It consists of two parts: Part 1 assesses safety and dosage, while Part 2 compares the efficacy of the two treatment combinations.
Study Timeline: The study began on December 28, 2023, with an estimated primary completion date in 2025. The last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study could significantly impact Regeneron’s stock performance and investor sentiment, especially if odronextamab proves more effective than the current standard treatment. Success in this study may position Regeneron favorably against competitors in the oncology market, potentially leading to increased market share and investor confidence.
The study is ongoing, and further details are available on the ClinicalTrials portal.